Watching her beloved aunt, a vibrant 75-year-old teacher, succumb to dementia ignited a lifelong mission for Dr. Fanny Ip Chui-fun to uncover solutions for brain degeneration. As the chief scientific officer at the Hong Kong Centre for Neurodegenerative Diseases (HKCeND), she has dedicated her career to tackling dementia, a condition projected to affect 152 million people globally by 2050.
Ip believes traditional Chinese medicine (TCM) offers valuable insights into brain health. Rooted in the concept of body harmony, TCM views brain health issues as imbalances within interconnected organ systems. Remedies aim to restore balance, improve brain function, and promote overall well-being.
Recent studies highlight TCM’s promising role in dementia prevention. For example, TCM positively influences gut microbiota, an essential component of the gut-brain axis, and supports heart health, which is critical for cognitive function. Research also suggests that TCM may enhance neurogenesis—the formation of new neurons vital for memory and learning.
Key TCM ingredients such as curcumin, derived from turmeric, and Ginkgo biloba have gained recognition for their brain health benefits. Curcumin’s antioxidant and anti-inflammatory properties may protect nerve cells, while Ginkgo biloba, known as the “brain herb,” has been linked to improved cognitive function, immunity, and synaptic communication. However, understanding how these ingredients work together remains a challenge.
“Traditional Chinese medicines often contain multiple ingredients that interact in complex ways,” Ip explains. Her research focuses on studying how these combinations support synapses—the critical connections between neurons responsible for transmitting messages. Synaptic deterioration is closely linked to cognitive decline.
Ip co-founded the HKUST start-up Infitech, which develops brain health products like the Cogniherbs line. The NerveReform supplement, inspired by Qing dynasty dietary prescriptions for “forgetfulness,” aims to restore synaptic function and combat early brain degeneration.
Beyond treatments, early detection is a priority. Ip’s team has made strides in identifying biomarkers—measurable indicators in blood and tissues—that flag risks of mild cognitive impairment (MCI) and Alzheimer’s disease (AD). These biomarkers also assess the effectiveness of TCM interventions in slowing cognitive decline.
By integrating biomarkers and TCM, Ip envisions personalized treatments to combat dementia. Her work bridges ancient practices with modern science, paving the way for validated therapies to address this growing global challenge.
READ MORE: